Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tuspetinib
- Development stage
- Phase 2
- Lead developer
- Aptose Biosciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tuspetinib is a potent oral small molecule myeloid kinase inhibitor (MKI) in clinical development for the treatment of acute myeloid leukemia (AML). It is designed to simultaneously inhibit a select set of kinases that drive prosurvival and drug resistance pathways in myeloid malignancies. Tuspetinib targets key kinases including Spleen tyrosine kinase (SYK), wild-type and mutant forms of FMS-like tyrosine kinase 3 (FLT3), mutant Mast/stem cell growth factor receptor Kit (but not wild-type), Janus kinase 1/2, Ribosomal S6 kinase alpha-1/2 (RSK1/2), Mitogen activated protein kinase kinase kinase TAK1–TAB1 complex kinases, and indirectly suppresses MCL1 expression. This multikinase inhibition leads to suppression of multiple oncogenic signaling pathways such as STAT5, MEK/ERK, AKT/mTOR. Preclinical studies have shown that tuspetinib prolongs survival in AML models and demonstrates enhanced activity when combined with venetoclax or azacitidine. Clinical trials are ongoing for relapsed/refractory AML as monotherapy or in combination regimens[1][2][3][4][5][6][7][8].
- Other names
- tuspetinib
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)RPS6KA1 (Ribosomal S6 kinase Alpha-1)RPS6KA3 (RSK2)SYK (Spleen Tyrosine Kinase)TAB1 (Mitogen activated protein kinase kinase kinase TAK1-TAB1 complex)
Beyond the preview
Go deeper on tuspetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tuspetinib.